Table 3.
Laboratory findings before and after ezetimibe treatments
| Baseline | 24 weeks | P-value (95% CI) | |
|---|---|---|---|
| AST (IU/L) | 25.0 ± 11.3 | 26.8 ± 16.7 | 0.350 |
| ALT (IU/L) | 26.1 ± 14.7 | 26.8 ± 14.9 | 0.501 |
| γ-GTP (IU/L) | 54.9 ± 77.6 | 46.9 ± 63.9 | 0.054 |
| CPK (IU/L) | 143.5 ± 69.1 | 138.2 ± 81.9 | 0.726 |
| BUN (mg/dL) | 16.6 ± 5.0 | 17.3 ± 5.1 | 0.323 |
| Creatinine (mg/dL) | 0.81 ± 0.25 | 0.81 ± 0.26 | 0.324 |
| Uric acid (mg/dL) | 5.94 ± 1.46 | 5.95 ± 1.75 | 0.801 |
| Triglycerides (mg/dL)* | 188.7 (52–376) | 155.6 (54–777) | 0.002 (1.05 to 61.57) |
| HDL-cholesterol (mg/dL) | 50.0 ± 14.4 | 51.2 ± 15.6 | 0.444 |
| Non HDL-cholesterol (mg/dL) | 165.5 ± 37.1 | 134.8 ± 31.9 | 0.001 |
| LDL-cholesterol (mg/dL) | 131.8 ± 33.4 | 105.7 ± 28.4 | <0.001 |
| Fasting plasma glucose (mg/dL) | 105.3 ± 25.4 | 108.1 + 28.2 | 0.506 |
| Hemoglobin Alc (%) | 5.77 ± 0.61 | 5.69 ± 0.79 | 0.651 |
| Insulin (μU/mL)* | 14.5 (2.6–119.2) | 12.0 (2.4–270) | 0.211 (−1.87 to 7.67) |
| HOMA-IR* | 4.21 (0.65–40.2) | 3.08 (0.53–14.2) | 0.011 (−0.84 to 3.42) |
| White blood cell count (×102/mm3) | 6118 ± 1430 | 5710 ± 1316 | 0.403 |
| Hemoglobin (g/dL) | 14.3 ± 1.6 | 14.4 ± 1.7 | 0.324 |
| Platelet (×104/mm3) | 22.7 ± 4.8 | 22.8 ± 5.3 | 0.540 |
| High sensitivity CRP (mg/dL)* | 0.13 (0.011–1.200) | 0.11 (0.010–1.000) | 0.263 (−0.04 to 0.78) |
| RLP-c (mg/dL)* | 6.06 (1.6–18.9) | 7.52 (1.9–45.3) | 0.529 (−2.12 to 2.82) |
| Free fatty acid (mEq/dL) | 0.55 ± 0.28 | 0.47 ± 0.23 | 0.259 |
*
Data are means ± standard deviation, geometric mean and range. These variables are shown in the original scale after analysis using log (natural)-transformed values.
γ-GTP, γ-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, asparatate aminotransferase; BUN, blood urea nitrogen; CI, confidence interval; CPK, creatine phosphokinase; CRP, C-reactive protein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; RLP-c, remnant-like particle cholesterol.